Sama Resources (TSXV:SME)

Want to be invested in a Ron Netolitzky company with an excellent management team and a potential for a 10x return? Look no further than Sama Resources. 

I've covered Sama's exploration project in Ivory Coast before, but with the recent flare-up in post-election violence I wasn't sure if the project would be affected. It turns out that even during the brief period of hostility, the company's operations proceeded unimpeded. With the conclusion of hostilities Sama's share price quickly recovered and with good reason. Dr. Audet is running a very successful, and aggressive, exploration program that has already uncovered a significant Ni-Cu sulphide deposit, as well as a series of additional massive sulphide and laterite finds.

Dr. Audet has had significant experience mining for Nickel from his previous stint with Falconbridge, on a project adjacent to the current property. He has added a second drill to the project and is quickly expanding and defining what looks to be a major west African deposit.

This stock is very tightly held with close to 40% ownership by the insiders. There is a huge interest in the company from Africa-focused investors, as evidenced by their last financing. Short of a complete collapse in Ni price, I think Sama will do incredibly well as an investment.

There is a strong demand for shares in the low $0.50s, and the $0.55 warrants (expire on Sep 27/11) will provide additional liquidity as the share price moves higher. I will look to add more on any weakness during the summer.

Beaufield Resources (TSXV:BFD) 

Beaufield reported assays for 8 drill holes from its Tortigny poly-metallic project in Quebec. Results were some of the best intercepts of copper-zinc-silver in Canada in recent decades. 7 out of 8 holes returned dozens of meters of mineralization. One of the best holes was drilled through the center of the deposit, encountering several mineralized sections including 37.65 m of 6% Zn, 2.6% Cu, and 72g/t Ag. Cobalt and gold were also present in smaller grades, but also rare earth metals were extracted, including Gallium which is almost equivalent in price to Silver.

These are great results and they will undoubtedly help enhance the historic, near surface, deposit which is currently estimated at roughly 500k tonnes of ore at lower grades. There are also further 28 assay results which are expected sometime in June. Results from this round of drilling will be used in calculating the new 43-101 estimate.

This type of a VMS deposit typically has extensions which occur in clusters. Beaufield has identified several new geophysical targets on the property. Drilling of these targets is scheduled to start in May of this year.

Despite these great results, Beaufield has pulled back and is trading in the low $0.30s. Summery may be a great time to pickup more shares of Beaufield as the stock has the potential to deliver another surprising news and give us a great return on our investment, much like happened in September of 2010, when the stock took off from $0.18 to $0.68 in less than ten days.

Kane Biotech (TSXV:KNE)

Kane announced closing of its oversubscribed private placement. The company successfully raised $2.4M which is enough money for Kane to complete its clinical trial and even start up some of its other programs.

With Kane's success of late, the company's profile has risen dramatically and it has captured attention of a wider market. This company has a lot of surprises it can deliver on and is a great investment opportunity at these levels. I continue to buy Kane under $0.15.

Bioasis Technologies (TSXV:BTI)

Bioasis is starting to report on the much anticipated Transcend, Blood Brain Barrier crossing technology, program. Earlier in the month the company announced that the National Research Council of Canada had independently verified company's claims that it is capable of delivering a variety of therapeutic agents of small and large molecular weight into the cells in the brain.

On May 11th, the company further announced that it was initiating its first Transcend development program aimed at treatment for lysosomal storage disorders (LSD). LSD are devastating neurological diseases for which there is no effective cure. Despite this the market revenues for LSD have exceeded $2B in the past three years. Bioasis singles out Genzyme's drug Aldurazyme which had worldwide annual sales of $167 million.

Both these news releases were received with a lot of interest from the pharmaceutical industry. Through this program Bioasis will continue to prove Transcend's ability of delivering various therapeutics across the blood brain barrier, thereby showing many neurological conditions which were previously untreatable may soon be treatable with the help of Transcend.

These news releases signal important milestones for the company, but they were probably aimed more at the pharmaceutical industry, rather than the investors. Going forward we look towards Bioasis completing conjugation studies and hopefully landing some contracts with big pharmas. Bioasis' market cap is at $16M, while the company has the potential to significantly alter the central nervous system disease $100B market. The stock has strong support at these levels, and the upside is for a potential 10 bagger return. This is one of TB's favorite companies.